You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Passive Activity Monitoring with Patient Identification and Gesture Detection

    SBC: INGENIUM CARE, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Elderly patients with Alzheimer's disease and dementia present a massive care challenge for family members and care professionals. In the last year of a patient's life, half of family caregivers report spending 46 or more hours a week assisting him/her with activities of daily living (ADL). Ingenium Care proposes to create a passive, self-learning, sy ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Tetravalent Vaccines for Dengue Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmission in tropical and subtropical areas and vaccines are an urgent public health priority. Although dengue rarely occurs in the continental United States, it is endemic in Puerto Rico, and in many popular ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccine research. An increasing number of human monoclonal antibodies (mAbs) have been isolated in recent years from individuals who show remarkably broad and potent neutralizing responses. Coupled with pas ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Therapeutic Vaccines for Chronic HBV

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals but can also cause chronic infection, particularly in newborns infected by vertical transmission. Chronic hepatitis B infection is a significant global health issue directly affecting 350 million people ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. TITER ON CHIP: ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION

    SBC: INDEVR, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is a tremendous need for new analytical methods to enhance vaccine research and development, ultimately allowing the production of safe and efficacious vaccines in less time at less cost. For example, it is well known that for splt vaccines one step in the process that can be rate limiting is protein quantification and potency determination. The FDA appro ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affectingheart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves the lives of children with Pompe disease. The prognos ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. UHMWPE Composite Materials for Joint Implants

    SBC: TDA RESEARCH, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): In this SBIR Phase I project the key mechanical properties of ultrahigh molecular weight polyethylene (UHMWPE) joint implant materials will be improved by creating a composite material with carbon reinforcements. UHMWPEhas long been widely used in joint implants, and further improvements to its wear resistance have been obtained by cross-linking the polyethylen ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. DT-EGF Toxic Fusion Protein for Treatment of Bladder Cancer

    SBC: Aurora Oncology, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Bladder cancer is the 4th most common cancer in the U.S. Accounting For ~70,000 new cases annually and ~15,000 deaths. Treatment of superficial bladder cancer by resection and BCG administration is unsuccessful in about40% of cases with recurrences that eventually require cystectomy or other aggressive therapy. Bladder cancers overexpress the epidermal growth f ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR Phase I: One Size Fits All, Affordable, Comfortable, Sound Activated, Self-R

    SBC: ASIUS TECHNOLOGIES, LLC            Topic: NIDCD

    DESCRIPTION (provided by applicant): This study focuses on the production and testing of prototypes of a new inflatable technology for coupling sound into the human ear, for hearing aids. The technology has the potential to dramatically reduce the cost, and increase the safety and convenience of fitting a pair of hearing aids to a patient by eliminating the step of taking ea canal impressions and ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Tear-Resistant and Elastic Tissue Adhesive for Craniofacial Applications

    SBC: TDA RESEARCH, INC.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Alkyl 2-cyanoacrylates have been used as surgical glues and liquid band aids for years. Current cyanoacrylates have been approved by the Food and Drug Administration (FDA) to close incised skin, repair minor abrasions,and are used as a barrier against certain pathogens. Unfortunately, because of their limited tensile and tear strengths these adhesives cannot be ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government